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c-Abl kinase activity is regulated by a unique mecha-
nism involving the formation of an autoinhibited
conformation in which the N-terminal myristoyl
group binds intramolecularly to the myristoyl binding
site on the kinase domain and induces the bending of
the aI helix that creates a docking surface for the SH2
domain. Here, we report a small-molecule c-Abl
activator, DPH, that displays potent enzymatic and
cellular activity in stimulating c-Abl activation.
Structural analyses indicate that DPH binds to the
myristoyl binding site and prevents the formation of
the bent conformation of the aI helix through steric
hindrance, a mode of action distinct from the previ-
ously identified allosteric c-Abl inhibitor, GNF-2,
that also binds to the myristoyl binding site. DPH
represents the first cell-permeable, small-molecule
tool compound for c-Abl activation.
INTRODUCTION
Protein kinases are a key group of regulators of biological
processes, particularly the signal transduction pathways.
Consequently, the regulation of kinase activities constitutes an
essential element in maintaining normal cellular functions. The
activity of protein kinases can be modulated through several
mechanisms such as subcellular localization, interaction with
accessory proteins and ligands, and phosphorylation/dephos-
phorylation. One common mechanism of kinase activation is
the conformational reorganization of the activation loop located
between the N- and C-lobes of the kinase domain. This confor-
mational change is prompted by phosphorylation of key
residue(s) on/near the activation loop. Additionally, global
conformational changes and/or reorganization of the domain
structures can also contribute to kinase activation.
In the area of kinase regulation, c-Abl kinase serves as an
example of how conformational changes, coupled with proteinChemistry & Biology 18, 177phosphorylation, modulate its kinase activity. c-Abl is a nonre-
ceptor tyrosine kinase that shares sequence homology with
the Src kinase family (Wang, 1993). Like other members of the
Src family, the N-terminal portion of c-Abl is composed of three
Src homology domains (SH1/catalytic, SH2, and SH3 domains).
c-Abl also contains a unique N-terminal cap (80 amino acids)
that plays an important role in the regulation of its kinase activity.
The C-terminal portion of c-Abl is composed of an array of
signaling and recognition domains that are involved in specific
cellular functions of c-Abl, including a DNA-binding domain,
an actin-binding domain, several docking sites for partner
proteins, and nuclear localization/export signals. c-Abl localizes
to both the nucleus and cytoplasm. Evidence suggests that
nuclear c-Abl is involved in cell-cycle regulation and stress
responses to DNA damage, oxidation, and ionization whereas
cytoplasmic c-Abl plays a role in morphogenesis, F-actin
dynamics, and signal transduction induced by extracellular
stimuli (Taagepera et al., 1998; Wang, 1993; Van Etten, 1999;
Sirvent et al., 2008). There are two human c-Abl isoforms,
c-Abl 1a and 1b, derived from alternative splicing events (Shtivel-
man et al., 1986). They differ only in the N-terminal cap region.
c-Abl 1b is 19 amino acids longer and is myristoylated on the
N-terminal glycine, whereas c-Abl 1a is not myristoylated. This
difference has important implications in the regulation of the
c-Abl kinase activity.
c-Abl is normally maintained in its inactive state in the cell.
Over the years, its mechanism of regulation remained largely
unknown. Although its N-terminal region shares significant
homology with the Src family kinases, it does not contain the
C-terminal tyrosine that plays an essential role in the regulation
of Src kinase activity (Xu et al., 1997; Williams et al., 1997).
Recently, crystal structures of the N-terminal portion of c-Abl
1b have been resolved that shed light on the potential regulatory
mechanism of this enzyme (Nagar et al., 2003, 2006). This
portion of c-Abl contains minimally required components for
the proper regulation of the kinase activity. Based on the struc-
tural data, it was proposed that the c-Abl kinase activity is
inhibited through the formation of an assembled conformation
(Figure 1). In this state, the N-terminal myristoyl group binds
to a deep and largely hydrophobic pocket, often called the–186, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 177
Figure 1. Autoinhibited, Assembled c-Abl Structure (PDB code:
1OPK) with a Myristoyl Group
Helix aI0 is highlighted in smudge green. An overlay of the c-Abl kinase domain
only structure (PDB code: 1M52) is colored yellow to highlight difference in
respective aI helixes with and without SH2 and N-terminal myristoyl.
Chemistry & Biology
Cell-Permeable Small-Molecule c-Abl Activatormyristoyl binding site, on the C-lobe of the kinase domain.
This binding helps form a compact conformation in which the
SH2 domain docks onto the kinase domain and the SH3 domain
interacts with both the kinase domain and the linker between the
SH2 and the kinase domain. In this compact conformation, the
structural plasticity of the N- and C-lobes required for catalysis
is restricted and the enzyme is in an autoinhibited state.
One key feature of thismechanism is the bending of the aI helix
on the C-lobe of the kinase domain induced by N-terminal
myristoyl binding to the myristoyl binding site. The bending of
the aI helix starts at Phe516 and is followed by a short loop
and concluded by a new three-turn helix, called the aI’ helix (Fig-
ure 1). This sharp bend of the aI helix is required to form adocking
surface for the SH2 domain. When the myristoyl group is dis-
lodged from the myristoyl binding site, the aI helix then adopts
an extended and straight conformation (Figure 1) which clashes
with the SH2 domain and prevents its docking onto the kinase
domain (Nagar et al., 2003). The resulting open conformation
has an elongated shape with the SH2 domain residing on top
of the N-lobe of the kinase domain and the SH3 domain
completely dissociated from the kinase domain (Nagar et al.,
2006). c-Abl kinase in this open conformation has elevated
kinase activity (partial activation) which triggers the autoactiva-
tion cycle by phosphorylating Y412 on the activation loop and
Y245 in the linker between the SH2 and the kinase domains.
Full activation of c-Abl is achieved following the phosphorylation
of these two key tyrosine residues (Brasher and Van Etten, 2000).
Various pieces of evidence support this model of c-Abl activa-
tion. For example, mutations in the SH2 and SH3 domains that
could potentially disrupt domain interactions lead to c-Abl acti-
vation (Brasher and Van Etten, 2000; Mayer and Baltimore,178 Chemistry & Biology 18, 177–186, February 25, 2011 ª2011 Else1994; Brasher et al., 2001; Hantschel et al., 2003). Furthermore,
mutations inside themyristoyl binding site that introduce bulky or
polar groups lead to c-Abl activation, presumably by affecting
the binding of the N-terminal myristoyl group to this site (Hant-
schel et al., 2003). N-terminal deletion through gene fusion
results in the constitutively active Bcr-Abl protein which is the
driver oncoprotein for the development of chronic myelogenous
leukemia (CML).
Since aberrant kinase activation is involved in many disease
states, especially in the onset and development of cancer,
kinase inhibition has been an active area of research for devel-
oping new therapeutics. Although less effort has been devoted
to the development of kinase activators compared to ATP-
binding inhibitors, some examples can be found in a recent
review (Simpson et al., 2009). It is becoming clearer that
specific kinase activators can not only serve as important tools
for enhancing our understanding of kinase regulation, but also
have therapeutic applications in a growing number of diseases.
Recent publications suggest a role of c-Abl activation in inhib-
iting mammary tumorigenesis and breast cancer cell mobility
and invasiveness (Allington et al., 2009; Noren et al., 2006).
c-Abl activation also has potential applications in treating neu-
tropenia since it has been suggested that c-Abl is critical in
maintaining normal myelopoiesis (Caracciolo et al., 1989; Rosti
et al., 1995). Therefore, we have selected c-Abl 1b (henceforth
referred to as c-Abl) as a model system for a kinase activator
screening effort. The goal of this exercise was to identify cell-
permeable, small-molecule tool compounds that potently
activate c-Abl kinase activity both in vitro and in the cell. These
specific c-Abl kinase activators will enable further analyses
of the complex c-Abl biology, especially of how activation of
c-Abl differentiates functionally from the constitutively active
Bcr-Abl.
Through this work, we have identified a small-molecule, DPH,
that binds to the myristoyl binding site and leads to activation of
c-Abl kinase activity. This molecule also demonstrates robust
cellular activity in stimulating the phosphorylation of c-Abl
and its downstream substrate, Crk. The crystal structure of this
activator with the c-Abl kinase domain suggests a potential
mechanism of activation that is consistent with the proposed
model. The significance and implications of this finding, along
with a recently published small-molecule c-Abl inhibitor
(GNF-2) that binds to the same myristoyl binding site (Zhang
et al., 2010; Adrian et al., 2006), are discussed.
RESULTS
Discovery of c-Abl Activator, DPH
A high-throughput screening (HTS) campaign against the
GlaxoSmithKline (GSK) internal compound library was carried
out to identify c-Abl activators (Cottom et al., 2011). Unlike
in vivo, c-Abl can be activated in the presence of ATP alone,
although at a very slow rate, in vitro. Therefore, the screening
was designed to look for small molecules that could further
enhance the rate of c-Abl activation in the presence of ATP.
The N-terminal catalytic domain of c-Abl enzyme used in this
screening (c-Abl1-531) has been shown to be in its inactive state
and is fully activatable (see Figure S1A available online), hence
suitable for activator screening.vier Ltd All rights reserved
Figure 2. Effect of DPH on c-Abl Activation
and Kinase Activity
(A) Structure of DPH. The chiral center is repre-
sented by an asterisk (*).
(B) Effect of DPH on c-Abl1-531 activation in the end
point c-Abl activation assay (Cottom et al., 2011).
A 3-fold dilution of DPH was carried out in DMSO
with a top concentration of 50 mM. The c-Abl
activation reactions were carried out as described
(Cottom et al., 2011) in the presence of various
concentrations of DPH. A pEC50 of 6.1 ± 0.03 is
obtained from data fitting which corresponds to
an EC50 of 794 nM. Data are represented as
mean ± SD.
(C) Kinase activity of fully activated c-Abl was
measured in the presence of various concentra-
tions of DPH (50, 10, 2, 0.4, 0.08, and 0.016 mM)
in a filter binding activity assay (Cottom et al.,
2011). % activity = percentage of kinase activity
in the presence of DPH relative to the control
activity that was measured in the absence of
DPH which was set as 100%.
See also Figure S1.
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characterization of c-Abl activators: an end-point activation
assay (IMAP) used in HTS, and a continuous activation assay
(Omnia) described in the next section. The end-point IMAP assay
is a two-step assay. In this assay, c-Abl is first activated in the
presence of ATP and a small-molecule compound for 10 min.
A peptide substrate is then added to measure the c-Abl kinase
activity acquired in the first step (Cottom et al., 2011).
DPH (5-[3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl]-2,4-
imidazolidinedione or 5-(1,3-diaryl-1H-pyrazol-4-yl)hydantoin)
(Figure 2A) was identified as a c-Abl activator from HTS. A
dose-response analysis of DPH in the end-point activation assay
(IMAP) using the inactive c-Abl1-531 gave a pEC50 of 6.1 ± 0.03
(EC50 = 794 nM) (Figure 2B). DPH also stimulates in vitro c-Abl
phosphorylation (Figure S1B).
Further Characterization of the Activation Effect of DPH
Since the end-point activation assay contains both c-Abl activa-
tion and activity steps, activation by DPH could be a result of the
compound effect on c-Abl activation, its kinase activity, or both.
To further dissect the mechanism of activation by DPH, high
concentrations of c-Abl1-531 (2 mM) and ATP (500 mM) were
incubated for 1 hr to preactivate c-Abl1-531 and its activity was
then measured in the presence of DPH. Since c-Abl was fully
activated, this reaction only measured the effect of DPH on the
kinase activity of c-Abl. As shown in Figure 2C, DPHhas no effect
on the kinase activity of c-Abl within the same concentration
range used in Figure 2B. This study indicates that DPH acts
through stimulating c-Abl activation, rather than its kinase
activity.
One limitation of the end-point activation assay is that the
selection of assay end-point could affect the activator potency
measured from the assay (Kenakin, 2006). In order to determineChemistry & Biology 18, 177the true potency of DPH, the continuous activation assay
(Omnia) was employed. This assay utilizes an Omnia peptide
that emits fluorescence upon phosphorylation (Shults et al.,
2006), allowing the continuousmonitoring of c-Abl kinase activity
during its activation. This analysis takes into consideration the
entire activation progress curve, therefore avoiding errors intro-
duced by taking arbitrary assay end-points. As expected, when
preactivated c-Abl1-531 kinase was used in this assay, a linear
reaction progress curve was observed since the reaction rate
did not change over time (Figure 3A). However, unactivated
c-Abl1-531, when used in this reaction, was gradually activated
which resulted inacurvilinear reactionprogresscurve (Figure3A).
This progress curve contains the initial phase (inactivated), the
transition phase (partially activated) and the final phase (fully acti-
vated). The relaxation time (t) is defined by the rate at which the
reaction transitions from the initial to the final phase. When
DPH was titrated in this reaction, an activation effect was
observed by a dose-dependent shortening of the relaxation
time, indicating a faster rate of c-Abl activation (Figures 3A and
3B). The relaxation time at infinite DPH concentration (t min) was
obtained by plotting the relaxation time against the DPH concen-
tration andfitting thedata toEquation 3 (Figure 3B). Since the tmin
value was fitted by extrapolating [DPH] to infinity in which the full
potency of DPH is realized, the 4-fold activation determined in
this analysis [(tmax – tmin)/ tmin] represents the intrinsic activation
capacity of DPH.
DPH Binds to the Myristoyl Binding Site of c-Abl
Based on the crystal structure, the N-terminal myristoyl group
of c-Abl binds to the myristoyl binding site on the C-lobe of the
kinase domain and this binding helps maintain the inactive
conformation of c-Abl (Figure 1). To determine if DPH induces
c-Abl activation by binding to the myristoyl binding site to–186, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 179
Figure 3. Determination of the Intrinsic Activation Potency of DPH
in the Continuous c-Abl Activation Assay
(A) Progress curve analysis of c-Abl1-531 activation in the presence of DPH. In
this analysis, DPH and unactivated c-Abl were mixed in the presence of 50 mM
ATP and 26 mMOmnia peptide. The reaction progress curves were monitored
at various DPH concentrations (x, 0; +, 2.5;A, 7.6;>, 23;;, 69;7, 206;:,
617; D, 1852;-, 5556;,, 16,667;C, 50,000 nM). Solid lines represent fitting
of the data to Equation 1. A preactivated c-Abl was included as a control (B)
which gave a linear reaction progress curve. From this analysis, the relaxation
time (t) of c-Abl activation was determined by Equation 2 at each DPH concen-
tration.
(B) The relaxation time was plotted against DPH concentration and fitted to
Equation 3 to generate a 4-fold intrinsic activation activity of DPH. The EC50
determined in this assay does not reflect the true binding affinity between
the activator and the enzyme since this parameter is also affected by the
kinetics of the c-Abl autoactivation reaction.
Figure 4. DPH Displaces the Peptide Ligand from the Myristoyl
Binding Site in the Fluorescence Polarization Assay
The reactions were carried out in the presence of 160 nM c-Abl46-534 (D382N),
30 nM peptide ligand and various concentrations of DPH (25 mM top concen-
tration, 3-fold dilution). The binding Kd from this analysis is 137 ± 7 nM. Data
are represented as mean ± SD. See also Figure S2.
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tion (FP) competition binding assay was utilized.
This assay used a kinase-dead, N-terminal truncated
c-Abl46-534 (D382N) and a TAMRA-labeled peptide ligand that
bears the same sequence as c-Abl 1b N terminus (underlined)
with a myristoyl group (Myr-GQQPGKVLGDQRRPSL(K-TAMRA)
G-amide; Myr: myristoyl group). Truncation of the N terminus of
c-Abl produces an emptymyristoyl pocket for peptide ligand and
small-molecule binding. The kinase-dead mutation prevents180 Chemistry & Biology 18, 177–186, February 25, 2011 ª2011 Elseprotein phosphorylation and enables the generation of a more
homogeneous protein prep. Binding of the peptide ligand to
the myristoyl site of c-Abl can compete with small molecules
that also bind to this site. The displacement of the peptide ligand
leads to a change in fluorescence anisotropy which can be used
to calculate the binding affinity of the small molecules.
The binding of the peptide ligand to c-Abl was confirmed in the
FP binding experiment with a binding Kd of 38 nM (Figure S2A).
When a control peptide with an identical amino acid sequence to
that of the ligand peptide, but lacking the myristoyl group, was
used in the binding assay, no anisotropy change was observed
(Figure S2B), indicating that the binding is specific and requires
the presence of the myristoyl group. When ATP was used in
the assay, no competition with the peptide ligand was observed,
indicating that the peptide ligand does not bind to the ATP
pocket (Figure S2C). These data, taken together, strongly
suggest that the peptide ligand binds specifically to themyristoyl
binding site on c-Abl.
When DPH was tested in the FP competition binding assay,
a clear dose-response effect was observed with a fitted Kd of
137 ± 7 nM (Figure 4). These data indicate that DPH interacts
with c-Abl in the myristoyl binding site. DPH is a racemic mixture
of two enantiomers. When these two enantiomers were sepa-
rated and tested individually in the FP binding assay and the
end-point c-Abl activation assay, they displayed different activ-
ities. One enantiomer was active in both assays with a binding
pIC50 of 6.4 (IC50 = 398 nM) and activation pEC50 of 6.6
(EC50 = 251 nM), whereas the other lost 20-fold activity in
both assays (a binding pIC50 of 5.1 and activation pEC50 of
5.3). These results suggest that a specific configuration of DPH
is required for its binding to the myristoyl binding pocket.
Cocrystal Structure of DPH with the c-Abl
Kinase Domain
The above FP binding data strongly suggest that DPH binds
to the myristoyl binding site of c-Abl. To gain a bettervier Ltd All rights reserved
Figure 5. The Cocrystal Structure of R-DPH and the c-Abl248-531
(A) Packing of crystal asymmetric unit. Chain B (cyan) shows a longer aI helix
ending at residue 529 and packing against chain A (green). The aI helix for
chain A is only visible to residue 519. The remaining residues, 520–531, are
disordered and not visible. DPH is rendered as yellow sticks for carbon, red
for oxygen, blue for nitrogen, and white for fluorine.
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Chemistry & Biology 18, 177understanding of the molecular interactions that govern the
binding, a cocrystal structure of the more active enantiomer of
DPH with the c-Abl kinase domain spanning residues 248 to
531 (c-Abl248-531) was obtained. Crystals diffracted to 1.85 A˚
resolution with space group P212121 and cell parameters of a =
74.39 A˚, b = 95.43 A˚, and c = 115.50 A˚ and two molecules in
the asymmetric unit (Figure 5A and Table 1). The crystal structure
(Figure 5B) shows that the more active enantiomer has R config-
uration and thus is referred to asR-DPH.R-DPH binds to c-Abl in
themyristoyl binding site and straightens the aI’ helix to elongate
the aI helix (Figure 5A). In chain A, the aI helix extends to residue
519 and in Chain B, the aI helix extends to residue 529. The
remaining C-terminal residues of the respective molecules in
the asymmetric unit are disordered. In contrast, the autoinhibited
c-Abl has aI helix ending at residue 515, with a loop between
residues 515–521 and with aI’ helix defined by residues
521–529 (Figure 1). The elongated aI helix of Chain B with
R-DPH shows significant crystal packing and is an artifact of
crystallization. However, the C terminus of Chain A with R-DPH
shows no crystal packing and will be the focus of subsequent
discussion.
The fluorophenyl ring of R-DPH occupies a hydrophobic
pocket defined by Leu359, Leu360, Ala363, Val487, Leu448,
and Phe512 (Figure 5B). The 2-NH of the hydantoin ring of
R-DPH is hydrogen-bonded to the side chain of Tyr454 via
a mediating water molecule, while the 4-NH of the hydantoin
forms a direct hydrogen bond with the backbone carbonyl group
of Glu481. The pyrazole core of R-DPH has Van der Waals
contacts with Pro484. The phenyl ring extends toward the elon-
gated aI helix and sits in a lipophilic groove with Ala356 and
Pro484 defining respective walls of the groove. One edge of
the phenyl ring is solvent exposed.
Contrary to what is seen with the R-DPH bound structure
where the aI helix is in the extended conformation, c-Abl with
GNF-2 (Zhang et al., 2010) shows that the aI helix stops at
Phe516 and the aI’ helix defined by residues 521–529 packs
against GNF-2, similar to what is seen in the myristoyl-bound
autoinhibited c-Abl structure (Figure 1). An overlay of the
R-DPH structure with the GNF-2 bound c-Abl structure illus-
trates the significant conformational differences in the aI and
aI’ helices (Figure 5C). The phenyl ring ofR-DPH occupies space
where aI’ helix would reside in the inhibited form of c-Abl with
GNF-2. These structural differences provide the basis for the
opposing effects of GNF-2 and DPH on c-Abl activity.
DPH Is Cell Permeable and Stimulates Full-Length
c-Abl Activation in HEK-MSRII Cells
So far, our data have demonstrated that DPH is a potent
activator of N-terminal kinase domain (1-531) of c-Abl in vitro.(B) Interactions of R-DPH (yellow) and the c-Abl myristoyl site. Key amino acid
residues are rendered as sticks with labels. Key hydrogen bonding interactions
are indicated with dashed lines and are annotated with distances (A˚). 2-NH
hydrogen bonds to a water molecule and 4-NH hydrogen bonds to E481. Fig-
ure inset (upper left) shows the electron density for R-DPH.
(C) Overlay of the cocrystal structures of R-DPH (yellow) and GNF-2 (cyan,
PDB code 3K5V) bound to the c-Abl kinase C-lobe domains (green and
orange, respectively). The dots represent the Van der Waals surface of I521
and V525 to illustrate the overlap with the space occupied by the phenyl group
of DPH.
–186, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 181
Table 1. Data Collection and Refinement Statistics for the
Cocrystal Structure of R-DPH and c-Abl248-531
R-DPH w/ c-Abl Kinase Domain
Data collection
Space group P212121
Cell dimensions
a, b, c (A˚) 74.39, 95.43, 115.50
a, b, g () 90, 90, 90
Resolution (A˚) 30–1.85 (1.9–1.85)a
Rsym or Rmerge 0.048 (0.502)
I / sI 41 (2.7)
Completeness (%) 99 (98.3)
Redundancy 5 (4.9)
Refinement
Resolution (A˚) 30–1.85
No. reflections 66950
Rwork / Rfree 0.189/0.204
No. atoms
Protein 4250
Ligand/ion 160
Water 215
B factors
Protein 33.9
Ligand/ion 35.6
Water 33.7
Rmsd
Bond lengths (A˚) 0.007
Bond angles () 1.076
a Values in parentheses are for highest resolution shell.
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length c-Abl in the cell, the cellular effect of DPHwas determined
by measuring the phosphorylation status of Y245 and Y412 of
c-Abl upon DPH treatment as a surrogate for c-Abl activation
in cells. Such c-Abl phosphorylation can be induced by pervana-
date or growth factor treatments. However, in our hands,
commercially available pY412 and pY245 antibodies were
insensitive in detecting DPH-stimulated endogenous c-Abl
phosphorylation by western blot (Figure 6A, lanes 1–4, and Fig-
ure 6B, lane 1). We hypothesize that the c-Abl phosphorylation is
milder with DPH, than with more strenuous treatments, such as
pervanadate or growth factor treatments, that may be inducing
multiple pathways of activation of c-Abl. To overcome this diffi-
culty, we overexpressed human c-Abl 1b (full length) in HEK-
MSRII cells by BacMam transduction (Cottom et al., 2011),
which improved western blot detection of pY245 and pY412
c-Abl in cell lysates. As shown in Figures 6A and 6B, DPH
induced both pY245 and pY412 c-Abl phosphorylation. In addi-
tion to pY245 and pY412 bands, these antibodies detectedmany
nonspecific bands which were also induced by DPH treatment.
Interestingly, the inductions of specific, as well as nonspecific,
bands in response to DPH treatment were completely abrogated
by imatinib (Figure 6A), suggesting that the nonspecific bands
may be either substrates or breakdown products of c-Abl. To182 Chemistry & Biology 18, 177–186, February 25, 2011 ª2011 Elsefurther confirm the effect of DPH on Y412 phosphorylation, we
immunoprecipitated c-Abl from cells treated with DPH or
DMSO and determined the change in Y412 phosphorylation
upon treatment with DPH by mass spectrometric analysis. A
2.5- to 3-fold increase in Y412 phosphorylation by DPH
(10 mM) treatment (apparent phosphorylation stoichiometry
55%), as compared with cells treated with DMSO (apparent
phosphorylation stoichiometry 20%) was observed. The
cellular EC50 of DPH on Y245 phosphorylation was determined
to be 2.5 mM (pEC50 = 5.6 ± 0.2) in HEK-MSRII cells by InCell
western assay (Figure 6C). Taken together, these data strongly
indicate that DPH is cell-permeable and can activate full-length
c-Abl in cells.
DPH Induces the Phosphorylation of c-Abl Substrate Crk
In the above work, we demonstrated that Y245 and Y412 phos-
phorylation was induced upon treating the cells with DPH. To
test if DPH was able to activate endogenous c-Abl in cells, we
measured the phosphorylation of c-Abl substrate, Crk, in cells
that were treated with DPH. Crk is a well-characterized cellular
substrate of c-Abl. It is phosphorylated by active c-Abl. The
pCrk antibody we utilized recognizes pY221 of Crk and pY207
of Crk-L, a Crk isoform. We first treated KG-1, a human myeloid
cell line, with DPH and detected Crk-L pY207 by immunoblotting
as a readout for enhanced c-Abl kinase activity. In accordance to
our hypothesis, DPH induction of Crk-L pY207 in KG-1 cells was
dose dependent. Moreover, these inductions were completely
abolished by imatinib treatment, suggesting a dependence on
the c-Abl kinase activity (Figure 6D). We also developed
a western blot pCrk (pY221) assay for the detection of endoge-
nous c-Abl activation in HepG2 cell line. Consistent with c-Abl
pY245 InCell western analysis, a cellular EC50 of DPH of
2.5 mM (pEC50 = 5.6 ± 0.2) was also observed in the HepG2
pCrk assay (Figure 6E). These results confirmed DPH as a cell-
permeable small-molecule activator of c-Abl.
DISCUSSION
In this paper, we describe a small-molecule activator (DPH) of
the c-Abl kinase that was identified through HTS of a1.3million
compound library. We show that this molecule demonstrates
both enzymatic and cellular c-Abl activation activities. It stimu-
lates phosphorylation of c-Abl and only affects the activation
process of c-Abl with no effect on its kinase activity. Structural
studies demonstrate the binding of this small-molecule to the
myristoyl binding site and suggest a potential mechanism of
c-Abl activation by DPH.
c-Abl activation is an extremely dynamic process marked by
the disassembly of the compact autoinhibited conformation, fol-
lowed by the phosphorylation of two key Tyr residues (Y245 and
Y412). Based on structural data, the autoinhibited conformation
of c-Abl is maintained through the binding of the N-terminal
myristoyl group to the myristoyl binding site on the kinase
domain. This event provides specific intramolecular interactions
for the formation of the bent conformation of the aI helix which is
required for the docking of the SH2 domain onto the kinase
domain. These interactions appear to be mainly provided by
the myristoyl group with minimal contributions from the adjacent
tether peptide sequence, as a bent conformation of the aI helix isvier Ltd All rights reserved
Figure 6. DPH Activates c-Abl in Cells
(A) (B) DPH-induced phosphorylation of c-Abl Y245 (A) and Y412 (B). Immunoblots show the inductions in phosphorylation (pY245 and pY412) by DPH in
HEK-MSRII cells transduced with c-Abl. Imatinib inhibits Y245 phosphorylation induced by DPH.
(C) Dose response analysis of DPHonY245 phosphorylation in HEK-MSRII cells transducedwith c-Abl by InCell western assay (Cottomet al., 2011) gave a cellular
EC50 of 2.5 mM (pEC50 = 5.6 ± 0.2). The integrated intensity (800/700 nm) was calculated as described elsewhere (Cottom et al., 2011). Data are represented as
mean ± SD.
(D) Imatinib-sensitive dose-dependent induction of pY207 Crk-L in KG-1 cells treated with DPH.
(E) Dose-dependent induction in pY221 Crk in DPH-treated HepG2 cells by western blot analysis. Ratios of pixel intensities of pY221 Crk/total Crk in DPH treated
to DMSO control derived from the western blot was fitted in a nonlinear curve graph to give a cellular EC50 of 2.5 mM (pEC50 = 5.6 ± 0.2). Data are represented as
mean ± SD.
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added in trans (Nagar et al., 2003).
In principle, it is possible to find small molecules that bind to
the myristoyl binding site and provide molecular interactions
that either stabilize or destabilize the bent conformation of the
aI helix. Such molecules are expected to significantly affect the
c-Abl activation process. The identification of DPH from HTS
provided a unique opportunity for the study of c-Abl activation
mechanism. The site of interaction of this molecule with c-Abl
was mapped to the myristoyl binding site by both competition
binding and crystallographic studies. Furthermore, detailed
structural analyses suggest a potential mechanism of activation
by this molecule. The overlay of the structure of inactive c-Abl
with the structure of the c-Abl kinase domain bound to R-DPHChemistry & Biology 18, 177identifies steric clashes between the left hand side phenyl moiety
of R-DPH and the aI’ helix. These clashes can be clearly seen as
the phenyl moiety extending into the Van der Waals surface of
the aI’ helix, indicating that R-DPH is too bulky for aI helix to
adopt the bent conformation (Figure 5C). As described above,
the bent conformation of the C-terminal helix to form aI’ provides
a necessary platform for the docking of the SH2 domain and
formation of the autoinhibited c-Abl conformation. Inability to
form this bent conformation therefore leads to c-Abl activation.
During the preparation of this manuscript, we encountered one
recent publication from a different group on the identification
of small-moleculemyristoyl site-binding c-Abl activators through
a NMR-based fragment screening (Jahnke et al., 2010). Further
structural analysis indicated that the binding of these molecules–186, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 183
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conformation. These results are in full agreement with our data
and further validate the mechanism of action of this type of
c-Abl activators. However, DPH differs from these activators in
two important ways. The published c-Abl activators have weak
(micromolar) potency and show no cellular activity. In contrast,
DPH is more potent (with nanomolar potency), cell-permeable
and demonstrates robust cellular c-Abl activation activity. To
our knowledge, there are currently no cell-permeable tool
compounds available for c-Abl activation. Therefore, DPH repre-
sents the first such tool compound with immediate applications
in the study of in vivo c-Abl biology.
While compounds binding to the enzyme active site almost
invariably act as inhibitors simply by competing with the
substrate, allosteric binders can elicit differential responses
depending on the specific molecular interactions they induce.
Recently, a small-molecule inhibitor of c-Abl, GNF-2, was iden-
tified that also binds to the myristoyl binding site (Adrian et al.,
2006; Zhang et al., 2010). This molecule is structurally distinct
from DPH. Analysis based on the c-Abl/GNF-2 cocrystal struc-
ture suggests that GNF-2 interacts closely with the aI’ helix
and stabilizes its bent conformation (Figure 5C). Therefore, one
potential mechanism of GNF-2 inhibition could be its stabiliza-
tion of the autoinhibited c-Abl conformation. Such interaction
complements the function of the myristoyl group, especially in
the event that the N-terminal myristoyl group spontaneously
dissociate from the myristoyl binding pocket (Zhou, 2003).
Based on these observations, the following model can be
proposed to predict the effect of small-molecule modulators
that bind to the myristoyl pocket of c-Abl. The compound is
inhibitory if it stabilizes the bent conformation of the aI helix. It
is activating if it disrupts such bent conformation. Certain
compounds may bind in a way that neither disrupt nor reinforce
the bent conformation of the aI helix. These compounds act
merely as displacers of the myristoyl group and by doing so,
eliminate the stabilizing interactions on the bent conformation
of the aI helix induced by myristoyl group binding. Therefore,
such compounds are predicted to also act as c-Abl activators.
We have observed compounds of this nature in our lead optimi-
zation efforts and the results will be presented elsewhere.
In vivo, protein conformational states are stabilized/destabi-
lized not only by intramolecular forces, but also by interactions
with various ligands and protein partners. For example, strong
experimental evidence suggests that apart from the autoinhibi-
tion mechanism described so far in this paper, c-Abl inactive
state is likely also maintained by cellular binding proteins
that stabilize this autoinhibited conformation (Wang, 2004).
This complicates the study on c-Abl regulation because for
the most part, the nature of these proteins and their interac-
tions with c-Abl are unknown. However, it is likely that
a small-molecule activator identified in the in vitro setting could,
given sufficient potency, tip the balance between the active/
inactive states of c-Abl in vivo, trigger its autoactivation cycle,
and eventually lead to c-Abl activation. In support of this
hypothesis, we saw robust cellular c-Abl activation and Crk
phosphorylation upon DPH treatment. This potent cellular
activity of DPH enables further investigation of the roles of
c-Abl in processes such as myelopoiesis, tumorigenesis and
DNA damage responses.184 Chemistry & Biology 18, 177–186, February 25, 2011 ª2011 ElseSIGNIFICANCE
Although some progress has been made in understanding
the biochemical mechanism of c-Abl kinase activation
and identification of its cellular substrates, phenotypic
outcomes of c-Abl kinase activation in vivo remain elusive
due to the lack of a viable method to activate endogenous
c-Abl function. Recently, it was suggested that the activa-
tion of c-Abl/Crk pathway inhibits mammary tumorigenesis,
invasion, and metastasis (Allington et al., 2009; Noren et al.,
2006). It was also suggested that c-Abl is critical for the
normal myelopoiesis process (Caracciolo et al., 1989;
Rosti et al., 1995). Therefore, development of small-molecule
c-Abl activators allows further investigation of the
physiological as well as pathophysiological functions of
endogenous c-Abl. In this report, we identified a potent
cell-permeable c-Abl activator, DPH, that binds to the
myristoyl binding pocket of c-Abl, prevents the bending of
the aI helix and docking of the SH2 domain, and induces
c-Abl activation. Hence, themode of action of DPH confirms
the previously hypothesized mechanism for c-Abl activation
(Nagar et al., 2003, 2006). We showed that, in addition to its
in vitro activity, DPH also demonstrates robust cellular
activity in c-Abl activation. Therefore, the identification of
DPH provides a valuable tool molecule for the study of the
functions of endogenous c-Abl in a multitude of biological
processes.
EXPERIMENTAL PROCEDURES
Peptides used in the FP assay were custom synthesized by 21st Century
Biochemicals, LLC. Omnia peptide (Ac-KKGEAIYAAdP(Sox)G-NH2) was
purchased from Invitrogen (Omnia Y Peptide 6, Catalog # KNZ3061) (Shults
et al., 2006). All peptides were greater than 95% pure. Their identity was
confirmed by mass spectrometric analysis. All other reagents are of analytical
grade or higher.
Cloning, Expression, and Purification of c-Abl1-531, c-Abl46-534
(D382N) and c-Abl248-531 (kinase domain)
The full-length c-Abl lb cDNA (GenBank NM_007313) was generated by PCR
and cloned into pENTR/D-TOPO cloning vector as described by manufacturer
(Invitrogen Inc.). Cloning, expression, and purification of c-Abl1-531 has been
described elsewhere (Cottom et al., 2011). Cloning, expression, and purifica-
tion of c-Abl46-534 (D382N) and c-Abl248-531 were described in the Supple-
mental Experimental Procedures.
Continuous c-Abl Activation Assay
c-Abl activation was monitored continuously in a reaction mix containing ATP
(50 mM), theOmnia peptide and various concentrations of DPH (concentrations
indicated in text and/or figure legend) in 50 mM MOPS (pH 7.2), 2 mM MgCl2,
1mMDTT, 0.1 mg/ml BSA, 0.01% Tween-20, and 25mMNaCl. For the control
experiment, c-Abl1-531 (2 mM) was preactivated by incubating with 500 mMATP
for 1 hr at room temperature. To initiate the activation reactions, c-Abl1-531 was
added at a concentration of 0.5 nM with a final reaction volume of 20 ml. The
reactions were run in a black 384 well plate (Corning Costar #3658) and the
product formation was monitored by a continuous fluorescence detection
assay (Omnia assay, Invitrogen). Phosphorylation of the Omnia peptide was
quantified using an Envision 2102 fluorescence plate reader (PerkinElmer)
with an excitation and emission wavelength of 380 and 486 nm, respectively.
The c-Abl activation progress curves were fitted in Equation 1 describing
intermolecular enzyme activation during catalysis (Wu and Wang, 2003) for
the determination of the activation rate constant, kobs, which was further con-
verted to the relaxation time, t, by Equation 2 (Wu and Wang, 2003).vier Ltd All rights reserved
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C
k
ln

1 a1 ekobsEt+b (1)
t =
ln a
ða 1ÞkobsE (2)
In above equations, P is the amount of product, C is the specific activity of
fully activated c-Abl determined experimentally, kobs is the transition rate
constant, a is the fraction of active c-Abl at t = 0 (calculated as a ratio between
the basal activity and the full activity), E is total c-Abl concentration, t is time
and b is background.
The t values thus determined were then plotted against DPH concentrations
and the data were fitted to a general 4-parameter EC50 equation (Equation 3) to
generate t max, t min, Hill coefficient (h) and the EC50 values. In this equation,
t max and t min represent maximum and minimum value of t, respectively,
and [A] is DPH concentration.
The fold of activation was calculated, fold of activation = (t max – t min)/ t min.
t = tmin +

ðtmax  tminÞ=

1+ ð½A=EC50Þh

(3)
c-Abl Phosphorylation Gel Analysis
Total phosphorylation of c-Abl during activation wasmonitored by the incorpo-
ration of the 33P radiolabel onto the protein during the activation reactions with
[g-33P]ATP (10 mCi/ml, PerkinElmer). The c-Abl1-531 activation reactions were
carried out as described above in the presence or absence of DPH and
quenched at various times by the addition of the SDS-PAGE sample loading
buffer. Quenched samples were analyzed by SDS-PAGE and the amount of
33P incorporation in c-Abl was quantified by Phosphoimager (Storm,
MolecularDynamics).
Fluorescence Polarization Binding Assay
The FP binding assay was carried out in pH 7.2, 20 mMMOPS buffer contain-
ing 10mMMgCl2, 2mMCHAPS, 25mMNaCl, 0.1% pluronic acid, 0.05mg/ml
BSA, and 1 mM DTT. The final concentration of c-Abl46-534 (D382N) and the
peptide ligand (Myr-GQQPGKVLGDQRRPSL(K-TAMRA)G-amide) is 160 and
30 nM, respectively. The compound dilution was carried out in DMSO in
a 96-well, round-bottom polypropylene plate (Costar Catalog # 3359) and
was transferred (0.5 ml/well) to a black, round-bottom 384-well assay plate
(Costar catalog # 3658). DMSO (0.5 ml/well) was added for low control (peptide
ligand only) and high control (peptide ligand + c-Abl, no compound). Peptide
ligand in the above buffer was then added (5 ml/well) to the assay plate, fol-
lowed by the c-Abl mix (5 ml/well). Plate was vortexed slightly to mix and
was allowed to equilibrate for 30 min. Fluorescence anisotropy readout was
taken on an EnVision (PerkinElmer) 2102 fluorescence plate reader. The disso-
ciation constant (Kd) was determined using a method described previously
(Wang, 1995).
Synthesis and Characterization of DPH
To a solution of 3-(4-fluorophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (3 g,
11.27 mmol) and ammonium carbonate (4.33 g, 45.1 mmol) in ethanol (45 ml)
and water (45 ml), potassium cyanide (1.467 g, 22.53 mmol) in water (approx-
imately 5 ml) was added and stirred at 70C under nitrogen overnight. The
reaction was cooled in an ice bath, and then 2 M hydrochloric acid (30 ml,
60.0 mmol) was added dropwise to the reaction mixture. The solution was
left to stir for 3.5 hr. The mixture was added to EtOAc (200 ml) and extracted
with EtOAc. The EtOAc phase was washed with brine (63 200ml). The solvent
was evaporated to give the crude material of 5-[3-(4-fluorophenyl)-1-phenyl-
1H-pyrazol-4-yl]-2,4-imidazolidinedione as a yellow solid (3.3 g, 87%). Fifty
milligrams of the crude material was purified by reverse-phase preparative
LCMS to give the title compound (DPH) as a colorless solid (35.6 mg).
1H NMR (400 MHz, DMSO-d6): d 10.85 (br. s., 1H), 8.68 (s, 1H), 8.29
(d, J = 0.8 Hz, 1H), 7.93 (dd, J = 0.9, 8.7 Hz, 2H), 7.79–7.85 (m, 2H), 7.48–
7.55 (m, J = 7.6, 8.7 Hz, 2H), 7.28–7.37 (m, 3H), 5.26 (d, J = 0.8 Hz, 1H); 13C
NMR (101 MHz, DMSO-d6): d 174.6, 162.3 (d, J = 245.1 Hz), 157.0, 150.5,
139.2, 130.2 (d, J = 8.8 Hz), 129.5, 128.7 (d, J = 3.2 Hz), 128.3, 126.6, 118.3,
116.8, 115.5 (d, J = 21.6 Hz), 53.5; 19F NMR (376 MHz, DMSO-d6): d 114.1
(proton decoupled); HRMS (m/z): [MH]+ calcd. for C18H14FN4O2,
337.1101; found, 337.1100.Chemistry & Biology 18, 177Cocrystal Structure of DPH with c-Abl Kinase Domain (c-Abl248-531)
c-Abl248 – 531 was incubated overnight with 1 mM DPH and concentrated
to 20 mg/ml in 20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 3 mM DTT, and
5% (v/v) glycerol. Crystals were grown by hanging drop vapor diffusion with
200 nl protein and 200 nl reservoir solution at 4C. The reservoir solution
contained 0.4 M ammonium phosphate. Crystals grew in 1–5 days, were
transferred to reservoir solution with 15%–30% glycerol and flash-frozen in
liquid nitrogen.
Diffraction data were collected at 100 K using 0.97872 A˚ radiation at the
Advanced Photon Source at LifeScience CAT, beamline 21IDf using
a Mar225 CCD detector and then integrated and scaled with HKL2000 (Otwi-
nowski and Minor, 1997). Molecular Replacement solutions were found with
PHASER (McCoy et al., 2007) and refinement done with Phenix (Adams
et al., 2002). Model building was done with COOT (Emsley and Cowtan,
2004) and figures were made with PyMol (http://pymol.sourceforge.net/).
Stimulation of c-Abl Y245/Y412 Phosphorylation
in HEK-MSRII Cells by DPH
HEK-MSRII cells were transduced with BacMam c-Abl 1b virus. 48 hr after
transduction the cells were treated with DPH at 1–30 mM concentrations for
10 min. Cells pretreated with 5 mM of Imatinib for 10 min was used to identify
whether pY245 induction was depended on c-Abl kinase activity.
Stimulation of Crk-L Y207 Phosphorylation in KG-1 Cells by DPH
KG-1 cells (43 106) were seeded in 1ml of culture medium in 1.5 ml microcen-
trifuge tubes. Cells were incubated in a 37C water bath for 1 hr and treated
with DPH for 4 hr. After incubation, cells were pelleted by centrifugation at
1000 3 g for 5 min, washed twice in ice cold PBS, and subjected to cell lysis.
Stimulation of Crk Y221 Phosphorylation in HepG2 Cells by DPH
Cells (1.5 3 106) were plated in 60 mm dishes. One day after plating, the cells
were treated with DPH for 4 hr. The cells were then washed with ice cold PBS
and subjected to cell lysis.
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